TABLE 2.
Univariate analysis of PFS
| Covariate | Category | Univariate analysis | |
|---|---|---|---|
| HR (95% CI) | p value | ||
| Sex | Female | 1.109 (0.861–1.429) | 0.427 |
| Age | ≥65 | 0.855 (0.666–1.096) | 0.217 |
| Histology | Adenocarcinoma | 1.234 (0.971–1.569) | 0.085 |
| Clinical stage | IV | 1.605 (1.161–2.220) | 0.004* |
| ECOG PS | 2–3 | 3.109 (1.966–4.917) | <0.001* |
| Smoking status | Former/current | 0.732 (0.581–0.923) | 0.008* |
| Number of metastatic sites | ≥3 | 1.852 (1.389–2.469) | <0.001* |
| Line of immunotherapy | ≥3 | 1.401 (1.113–1.764) | 0.004* |
| Liver metastases | Yes | 1.958 (1.448–2.646) | <0.001* |
| Brain metastases | Yes | 1.303 (0.997–1.703) | 0.053 |
| Bone metastases | Yes | 1.451 (1.133–1.859) | 0.003* |
| NLR | ≥3 | 2.736 (2.158–3.470) | <0.001* |
| ≥4 | 2.890 (2.267–3.683) | <0.001* | |
| dNLR | >3 | 2.504 (1.906–3.290) | <0.001* |
| LDH (U/L) | >ULN | 1.873 (1.481–2.370) | <0.001* |
| ≥1.5*ULN | 3.398 (2.477–4.660) | <0.001* | |
| PLR | ≥160 | 1.552 (1.219–1.977) | <0.001* |
Abbreviations: dNLR, derived neutrophil‐to‐lymphocyte ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; NLR, neutrophil‐to‐lymphocyte ratio; PFS, progression‐free survival; PLR, platelet‐to‐lymphocyte ratio.
*
means p < 0.05.